42
Participants
Start Date
November 21, 2013
Primary Completion Date
January 31, 2017
Study Completion Date
April 3, 2018
Regorafenib (Stivarga, BAY73-4506)
Cetuximab (ERBITUX)
University of Pittsburgh Medical Center Health System, Pittsburgh
Washington University School of Medicine, St Louis
University of Colorado Hospital, Aurora
University of Southern California, Los Angeles
Lead Sponsor
Bayer
INDUSTRY